Insider · CIK 0001888829
Samsara BioCapital GP, LLC
Files at NGNE (Neurogene Inc.), VTVT (vTv Therapeutics Inc.). First filing Nov 27, 2024, latest Nov 27, 2024.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NGNE: Neurogene Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | Neurogene Inc. | $1.3M 48,770 shares | +3% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2024 | VTVT vTv Therapeutics Inc. | JOther Class A Common Stockindirect: By Samsara BioCapital, L.P. | -58,836 | - | - | 206,784 | Dec 6, 2024 |
| Mar 5, 2024 | VTVT vTv Therapeutics Inc. | AGrant or award Pre- Funded Warrants (Right to Buy)derivativeindirect: Samsara BioCapital, L.P. | +58,885 | - | - | 892,578 | Dec 6, 2024 |
| Nov 26, 2024 | NGNE Neurogene Inc. | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +20,748 | $24.91 | $517k | 1,689,105 | Nov 27, 2024 |
| Nov 26, 2024 | NGNE Neurogene Inc. | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +10,803 | $26.01 | $281k | 1,699,908 | Nov 27, 2024 |
| Nov 26, 2024 | NGNE Neurogene Inc. | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +15,219 | $26.73 | $407k | 1,715,127 | Nov 27, 2024 |
| Nov 26, 2024 | NGNE Neurogene Inc. | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +2,000 | $27.50 | $55k | 1,717,127 | Nov 27, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.